retatrutide update october 2025 Helped Adults With Obesity Lose Up to 30 Percent of Their Body Weight in New Trial Retatrutide Promises Big Weight Loss,

However, it comes at a cost

Without containing any real GLP-1 or GLP-1 receptor agonist , these patches cannot mimic the appetite suppression or weight loss often achieved through prescription medications

Combination Therapy: Often used alongside other hypoglycemic agents for enhanced efficacy

This triple mechanism of action distinguishes it from existing agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GLP-1/GIP receptor agonist), and is thought to produce more pronounced effects on weight reduction and metabolic control

[2] The primary side effects documented in clinical trials predominantly involve gastrointestinal symptoms, including nausea, vomiting, diarrhoea, and constipation

The most frequently reported adverse effects involve gastrointestinal symptoms, which typically emerge during the initial days to weeks of supplementation as the gut microbiome adjusts to the introduced bacterial strains